Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.96 EPS, up 34.38% or $0.33 from last year’s $-1.29 per share.

At the moment 2 analysts are watching Theravance Biopharma, Inc. (NASDAQ:TBPH), 0 rate it “Buy”, 0 “Outperform”, 2 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 2 analysts have a mean sales target of 5.06 million. For the quarter ending Sep-16, 2 analysts have a mean sales target of 5.78 million whilst for the year ending Dec-16, 2 analysts have a mean target of 36.55 million.

In terms of earnings per share, 2 analysts have a -1.19 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 2 analysts have a -1.22 EPS mean target and for the quarter ending Sep-16 there are 2 estimates of -4.35 EPS.

The biggest institutional shareholders in Theravance Biopharma, Inc. include GlaxoSmithKline PLC which owns 10 million shares in the company valued at $151.62 million. Woodford Investment Management LLP is the second biggest holder with 7 million shares currently valued at 128.30 million whilst Baupost Group LLC has 6 million shares valued at 105.22 million.

Total shares held by institutions as of the most recent company filings are 40,780,375 with a reported 2,622,355 bought and 879,463 sold. These holdings make up 73.08% of the company’s outstanding shares.

Currently insiders hold 174,457 shares in the business which makes up 0.45% of shares. The biggest holder currently is Rick E. Winningham who owns 882,056 shares (2.30% of those outstanding), whilst Mathai Mammen,M.D.,PhD holds 288,111 (0.75% of shares outstanding) and Mr. Bradford J. Shafer holds 251,165 (0.65% of shares outstanding).

The stock decreased 1.97% or $0.36 during the last trading session.